Treatment of lung squamous cell carcinoma with apatinib in patient who couldn't tolerate chemotherapy: A case report and literature review
10.13481/j.1671-587x.20180331
- Author:
Xiaoyue QUAN
1
Author Information
1. Department of Radiotherapy, First Hospital, Jilin University
- Publication Type:Journal Article
- Keywords:
Apatinib;
Lung squamous cell carcinoma;
Myelosuppression;
Overall;
Progression free survival
- From:
Journal of Jilin University(Medicine Edition)
2018;44(3):624-627
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the efficacy of apatinib in the treatment of a patient with lung squamous cell carcinoma who couldn' t tolerare the chemotherapy and review the literature, and to clarify the effectiveness of apatinib in order to provide the treatment reference. Methods: The patient was clearly diagnosed as stage Flung squamous cell carcinoma. After four cycles of chemotherapy, there was no significant change of the tumor volume, while the patient couldn' t tolerate the side effects caused by chemotherapy. Then the disease progressed rapidly. The primary lesion and multiple metastases responded significantly to the radiotherapy. However, the lesions were too extensive to radiotherapy, therefore, apatinib (500 mg • d-1, 40 d) was used to inhibit the progression of disease. Results: After the application of apatinib, the volumes of both lesions in chest wall and lung shrank greatly compared wtih before administration. The patient developed myelosuppression (grade E thrombocytopenia) and stopped taking apatinib. Then the volume of lesion in chest wall was increased. The dosage of apatinib reduced to 250 mg . d-1 , and the progression free survival (PFS) of the patient reached to 5 months. Conclusion: For the patients with lung squamous cell carcinoma who couldn ' t tolerate chemotherapy or fail in multiple lines of chemotherapy, apatinib has better efficacy with controllable side effects.
